Metformin Does Not Help Patients With Type of Pancreatic Cancer
While previous evidence indicated that metformin could help to fight the risk of cancer, a new study has determined that it does not help patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer. The research was done by Dr. Roongruedee Chaiteerakij of the division of gastroenterology and hepatology at the Mayo Clinic Cancer Center in Rochester, Minn.
The researchers looked at medical records from roughly 1,360 patients living with pancreatic ductal adenocarcinoma. The study indicated that the number of days of survival was 308 days, for the patients that did not take metformin in comparison to 292 days for the patients that did.
The study was done retrospectively and researchers say that the data should be used cautiously when trying to initiate clinical trials based on such results. The findings of the study were presented at the American Association for Cancer Research annual meeting in Philadelphia. The researchers also state that study findings that are released at conferences should be considered preliminary until published in a peer-reviewed medical journal.
- What Diabetes Supplies Should You Purchase? 29.02.2016